Dr. Feras Abdul Khalek

Claim this profile

Anne Arundel Medical Center

Studies Non-Small Cell Lung Cancer
Studies Lung Cancer
4 reported clinical trials
8 drugs studied

Area of expertise

1

Non-Small Cell Lung Cancer

Feras Abdul Khalek has run 3 trials for Non-Small Cell Lung Cancer. Some of their research focus areas include:

Stage II
Stage III
PD-L1 positive
2

Lung Cancer

Feras Abdul Khalek has run 3 trials for Lung Cancer. Some of their research focus areas include:

Stage II
Stage III
Stage I

Affiliated Hospitals

Image of trial facility.

Anne Arundel Medical Center

Image of trial facility.

Luminis Health Anne Arundel Medical Center

Clinical Trials Feras Abdul Khalek is currently running

Image of trial facility.

Immunotherapy + Chemotherapy

for Non-Small Cell Lung Cancer

This phase III ALCHEMIST treatment trial tests the addition of pembrolizumab to usual chemotherapy for the treatment of stage IIA, IIB, IIIA or IIIB non-small cell lung cancer that has been removed by surgery. Immunotherapy with monoclonal antibodies, such as pembrolizumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. Chemotherapy drugs, such as cisplatin, pemetrexed, carboplatin, gemcitabine hydrochloride, and paclitaxel, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Giving pembrolizumab with usual chemotherapy may help increase survival times in patients with stage IIA, IIB, IIIA or IIIB non-small cell lung cancer.

Recruiting

2 awards

Phase 3

27 criteria

Image of trial facility.

Targeted Therapy Screening

for Lung Cancer

This screening and multi-sub-study randomized phase II/III trial will establish a method for genomic screening of similar large cancer populations followed by assigning and accruing simultaneously to a multi-sub-study hybrid Master Protocol (Lung-MAP). The type of cancer trait (biomarker) will determine to which sub-study, within this protocol, a participant will be assigned to compare new targeted cancer therapy, designed to block the growth and spread of cancer, or combinations to standard of care therapy with the ultimate goal of being able to approve new targeted therapies in this setting. In addition, the protocol includes non-match sub-studies which will include all screened patients not eligible for any of the biomarker-driven sub-studies.

Recruiting

1 award

Phase 2 & 3

13 criteria

More about Feras Abdul Khalek

Clinical Trial Related

11 years of experience running clinical trials · Led 4 trials as a Principal Investigator · 2 Active Clinical Trials

Treatments Feras Abdul Khalek has experience with

  • Carboplatin
  • Gemcitabine Hydrochloride
  • Paclitaxel
  • Pembrolizumab
  • Pemetrexed Disodium
  • Biospecimen Collection

Other Doctors you might be interested in

Frequently asked questions

Do I need insurance to participate in a trial?

What does Feras Abdul Khalek specialize in?

Is Feras Abdul Khalek currently recruiting for clinical trials?

Are there any treatments that Feras Abdul Khalek has studied deeply?

What is the best way to schedule an appointment with Feras Abdul Khalek?

What is the office address of Feras Abdul Khalek?

Is there any support for travel costs?